Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): A review on toxicity profile and its management

Current Drug Safety

Volumn 11, Issue 1, 2016, Pages 62-68

  Sgambato, Assunta ^a   Casaluce, Francesca ^a   Sacco, Paola C ^b   Palazzolo, Giovanni ^c   Maione, Paolo ^b   Rossi, Antonio ^b   Ciardiello, Fortunato ^a   Gridelli, Cesare ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c Division of Medical Oncology   (Italy)

Author keywords

Immune related adverse events; Immunotherapy; Management toxicities; Nivolumab; PD 1 inhibitors; PD L1 inhibitors; Pembrolizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATEZOLIZUMAB; BMS 936559; DOCETAXEL; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURVIVAL; COLITIS; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; FATIGUE; HEALTH CARE QUALITY; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; IMMUNE RESPONSE; INFUSION RELATED REACTION; LIVER TOXICITY; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT RESPONSE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MANAGEMENT; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MANAGEMENT; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 84959869247     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574886311207040289     Document Type: Review

References (37)

1. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy - revisited. Nat Rev Drug Discov 2011; 10: 591-600.
2. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
3. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275-280.
4. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-82.
5. Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/ Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) - NCT01454102. Available at:http://https://clinicaltrials.gov// [Last accessed December 16th, 2014].
6. Gettinger SN, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 2014; 32: 5.
7. Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced nonsmall- cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. J Clin Oncol 2014; 32: 5.
8. Gettinger S, Rizvi N, Chow LQ, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) or erlotinib (ERL) in advanced non-small cell lung cancer. Ann Oncol 2014; 25: iv 361-72.
9. Rizvi NA, Chow LQM, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol 2014; 32: 5.
10. Antonia SJ, Gettinger SN, Chow LQM, et al. Nivolumab (anti-PD- 1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. J Clin Oncol 2014; 32: 5.
11. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; Published online February 20, 2015 http://dx.doi.org/10.1016/S1470-2045(15)70054-9
12. Spigel DR, Reckamp K, Rizvi N, et al. Phase III Study (CheckMate 017) of Nivolumab (Anti-Programmed Death-1) vs Docetaxel in Previously Treated Advanced or Metastatic Squamous (SQ) cell Non-small Cell Lung Cancer (NSCLC). Proceedings of the ASCO congress, May 2015, Chicago (USA); abstract 8009.
13. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, Randomized Trial (CheckMate 057) of Nivolumab versus Docetaxel in Advanced Non-squamous (non-SQ) Cell Non-small Cell Lung Cancer (NSCLC). Proceedings of the ASCO congress, May 2015, Chicago (USA); abstract LBA109.
14. An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) - NCT02041533. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014].
15. Garon B, Gandhi L, Rizvi N, et al. LBA43 - Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients with advanced NSCLC. Proceedings of the ESMO congress, September 28th, 2014, Madrid (Spain).
16. Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2014; 32: 8007.
17. Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) - NCT01905657. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014.
18. Horn L, Herbst RS, Spigel DR, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). Abstract MO18.01. Available at: https://www.webges.com/cview/library/wclc/home. Accessed December 2, 2013.
19. A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "FIR" - NCT01846416. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014.
20. A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" - NCT01903993. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014].
21. A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH" - NCT02031458. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014].
22. A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK" - NCT02008227. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014].
23. Segal NH. Poster presentation at the European society of clinical oncology meeting, Madrid, Spain, 26 September-30 September 2014. Abstract 5888.
24. Antonia S, et al. Poster presentation at the European society of clinical oncology meeting, Madrid, Spain, 26 September-30 September 2014. Abstract 5924.
25. A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ATLANTIC) - NCT02087423. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014].
26. Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer - NCT01352884. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014].
27. A Phase 1 Study to Evaluate AMP-514. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014].
28. MSB0010718C in Solid Tumors - NCT01772004. Available at:http://https://clinicaltrials.gov// [Last accessed December 30th, 2014].
29. Christopher Ryan Heery, Geraldine Helen O'Sullivan Coyne et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J Clin Oncol 2014; 32: 5.
30. Weber J. Clinical management of immunotherapy patients. Proceedings of the ESMO symposium of immuno-oncology, November 22nd 2014, Geneva (Switzerland).
31. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
32. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
33. Available at: http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
34. Weber JS, Kähler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30, 2691-97.
35. Robert C, Roussy G. Toxicity of immunotherapies with anti- CTLA-4 and anti-PD-1. Proceeding of the 2014 ESMO immuneoncology, Geneva (Swizterland).
36. Brahmer JR, Horn L, Antonia SJ, et al. Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients With Non-Small Cell Lung Cancer (NSCLC): Overall Survival and Long-term Safety in a Phase 1 Trial. Proceeding of the 2013 IASCL, Sydney (Australia).
37. Chow LQM. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. 2013 ASCO educational book; asco.org/edbook; e680-686.